Page 39 - Ace2 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

February 15, 2021 -- Researchers have identified interactions between short viral proteins and receptors that facilitate the entry of the SARS-CoV-2 virus into a host. This evidence of molecular links, published in Science Signaling on February 12, may help scientists identify drugs that are highly effective at blocking the virus. SARS-CoV-2 uses the angiotensin-converting enzyme 2 (ACE2) as a receptor to attach to host cells. ACE2 is a single-pass type I membrane protein with a short cytosolic C-terminal region. While SARS-CoV-2 primarily binds to ACE2 in the lungs, previous studies have re...

A new preprint research paper posted to the bioRxiv server demonstrates the potential of using the pre-existing protective responses to produce a broad-spectrum neutralizing response against not just SARS-CoV-2 but other future pathogens.

Scientists from Germany have determined the efficacy of currently used therapeutics in treating newer variants of SARS-CoV-2, including the UK, South Africa, and Brazil variants. Their findings reveal that both B.1.351 and B.1.1.248 variants are able to escape humoral immune responses induced by therapeutic antibodies, vaccinations, or natural SARS-CoV-2 infection.

Vaccine candidate containing tetanus toxoid potentially protective against SARS-CoV-2 Researchers from Cuba, China, and France have demonstrated the potential of coupling a viral antigen with the tetanus toxoid protein as a vaccination approach to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19). Tetanus toxoid (TT) is a chemically inactivated version of the tetanus toxin produced by the bacteria Clostridium tetani. This chemically inactivated antigen can be used as a protein carrier in vaccines to induce potent immune ...

A new study by researchers at the University of Connecticut Health Center, USA, reports the crucial nature of the pathogen pattern recognition receptor (PRRs), especially the two RLRs, retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated protein 5 (MDA5), in triggering host cell immune responses within the cell. The RLRs are viral RNA sensors.